Pure Bioscience, Inc. financial data

Symbol
PURE on OTC
Location
771 Jamacha Road #512, El Cajon, CA
Fiscal year end
July 31
Latest financial report
10-K - Q2 2025 - Oct 29, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 96.7 % -43.2%
Quick Ratio 11.4 % +1.43%
Debt-to-equity -120 % +31.4%
Return On Equity 54.2 % -72.8%
Return On Assets -266 % -0.57%
Operating Margin -103 % +36.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 112M shares +0.03%
Common Stock, Shares, Outstanding 112M shares +0.03%
Entity Public Float 4.67M USD -36.4%
Common Stock, Value, Issued 1.12M USD 0%
Weighted Average Number of Shares Outstanding, Basic 112M shares +0.01%
Weighted Average Number of Shares Outstanding, Diluted 112M shares +0.01%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.2M USD +12.4%
Revenue from Contract with Customer, Excluding Assessed Tax 2.2M USD +12.2%
Research and Development Expense 316K USD +4.64%
Operating Income (Loss) -2.27M USD +28.8%
Nonoperating Income (Expense) -127K USD +20.1%
Net Income (Loss) Attributable to Parent -2.4M USD +28.4%
Earnings Per Share, Basic 0 USD/shares +33.3%
Earnings Per Share, Diluted 0 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 334K USD -4.3%
Accounts Receivable, after Allowance for Credit Loss, Current 474K USD +59.1%
Inventory, Net 141K USD +152%
Assets, Current 1.05M USD +30.1%
Property, Plant and Equipment, Net 11K USD -15.4%
Assets 1.06M USD +29.3%
Accounts Payable, Current 784K USD +30.4%
Accrued Liabilities, Current 154K USD +16.7%
Liabilities, Current 938K USD +28%
Liabilities 6.17M USD +67.7%
Retained Earnings (Accumulated Deficit) -139M USD -1.76%
Stockholders' Equity Attributable to Parent -5.12M USD -78.6%
Liabilities and Equity 1.06M USD +29.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -503K USD -14.3%
Net Cash Provided by (Used in) Financing Activities 500K USD -36.3%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 112M shares +0.03%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -3K USD -101%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 409K USD -3.54%
Deferred Tax Assets, Valuation Allowance 29.3M USD -0.1%
Deferred Tax Assets, Gross 29.3M USD -0.1%
Depreciation 37K USD
Property, Plant and Equipment, Gross 1.62M USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 26.8M USD 0%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 133M USD +0.11%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 57K USD -28.8%
Interest Expense 111K USD +1133%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%